A Biomarker-Directed, Open Label, Multi-Centre Phase II Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With Non-Small Cell Lung Cancer
Latest Information Update: 26 Feb 2025
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 08 Jan 2024 Planned number of patients changed from 50 to 230, Parallel and randomized has been added to trial design, study phase changed to Phase 2/3, number of treatment arms changed from 1 to 2.
- 08 Jan 2024 Planned End Date changed from 30 Jul 2024 to 30 Jul 2027.